AU2020384456B2 - Orally disintegrating tablet - Google Patents

Orally disintegrating tablet

Info

Publication number
AU2020384456B2
AU2020384456B2 AU2020384456A AU2020384456A AU2020384456B2 AU 2020384456 B2 AU2020384456 B2 AU 2020384456B2 AU 2020384456 A AU2020384456 A AU 2020384456A AU 2020384456 A AU2020384456 A AU 2020384456A AU 2020384456 B2 AU2020384456 B2 AU 2020384456B2
Authority
AU
Australia
Prior art keywords
disorder
lubricant
orally disintegrating
mannitol
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020384456A
Other languages
English (en)
Other versions
AU2020384456A1 (en
Inventor
Taku KEMMOCHI
Mika KOSEKI
Yoshikazu Oka
Hiroyuki Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2020384456A1 publication Critical patent/AU2020384456A1/en
Application granted granted Critical
Publication of AU2020384456B2 publication Critical patent/AU2020384456B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020384456A 2019-11-11 2020-11-11 Orally disintegrating tablet Active AU2020384456B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/JP2019/044118 2019-11-11
PCT/JP2019/044118 WO2021095092A1 (ja) 2019-11-11 2019-11-11 口腔内崩壊錠
PCT/JP2020/042114 WO2021095779A1 (ja) 2019-11-11 2020-11-11 口腔内崩壊錠

Publications (2)

Publication Number Publication Date
AU2020384456A1 AU2020384456A1 (en) 2022-06-09
AU2020384456B2 true AU2020384456B2 (en) 2026-03-12

Family

ID=75911893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020384456A Active AU2020384456B2 (en) 2019-11-11 2020-11-11 Orally disintegrating tablet

Country Status (9)

Country Link
US (1) US20220387423A1 (https=)
EP (1) EP4059502A4 (https=)
JP (3) JP7395607B2 (https=)
CN (1) CN114650821A (https=)
AU (1) AU2020384456B2 (https=)
CA (1) CA3161119A1 (https=)
PH (1) PH12022551117A1 (https=)
TW (1) TWI873221B (https=)
WO (2) WO2021095092A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021095092A1 (ja) * 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠
EP4574134A1 (en) * 2023-12-22 2025-06-25 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising brexpiprazole

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160158227A1 (en) * 2011-10-14 2016-06-09 Otsuka Pharmaceutical Co., Ltd. Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1h-quinolin-2-one or a salt thereof
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010001106A1 (en) * 1996-04-16 2001-05-10 Tomohiro Yoshinari D-mannitol and its preparation
JP4358117B2 (ja) * 2001-03-06 2009-11-04 協和発酵キリン株式会社 口腔内速崩壊錠
US8153161B2 (en) * 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
JP3996626B2 (ja) * 2004-06-22 2007-10-24 塩野義製薬株式会社 口腔内速崩壊錠
JP5004236B2 (ja) * 2005-02-09 2012-08-22 キッセイ薬品工業株式会社 口腔内崩壊錠
BRPI0808889A2 (pt) * 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
US8431618B2 (en) * 2008-03-31 2013-04-30 Asahi Kasei Chemicals Corporation Processed starch powder with excellent disintegration properties and manufacturing method thereof
CN102119034B (zh) * 2008-06-13 2013-05-22 大日本住友制药株式会社 在口腔中快速崩解的片剂和制备其的方法
WO2010021300A1 (ja) * 2008-08-18 2010-02-25 三菱商事フードテック株式会社 新規マンニトール打錠用賦形剤
JP5337430B2 (ja) * 2008-08-26 2013-11-06 高田製薬株式会社 口腔内速崩壊錠
JP5466880B2 (ja) * 2009-05-20 2014-04-09 京都薬品工業株式会社 口腔内崩壊錠
JP5733930B2 (ja) * 2009-09-09 2015-06-10 武田薬品工業株式会社 固形製剤
US9827200B2 (en) * 2012-04-24 2017-11-28 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
JP5897196B1 (ja) * 2015-10-05 2016-03-30 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
CN105412036A (zh) * 2015-12-24 2016-03-23 北京康立生医药技术开发有限公司 依匹哌唑口腔崩解片
JP6201017B2 (ja) * 2016-08-04 2017-09-20 佐藤製薬株式会社 硬度及び崩壊性に優れた口腔内崩壊錠の製造方法及び該製造方法により製造される口腔内崩壊錠
WO2021095092A1 (ja) 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160158227A1 (en) * 2011-10-14 2016-06-09 Otsuka Pharmaceutical Co., Ltd. Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy)-1h-quinolin-2-one or a salt thereof
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法

Also Published As

Publication number Publication date
WO2021095779A1 (ja) 2021-05-20
CN114650821A (zh) 2022-06-21
TWI873221B (zh) 2025-02-21
TW202128167A (zh) 2021-08-01
EP4059502A4 (en) 2023-12-13
PH12022551117A1 (en) 2023-08-23
CA3161119A1 (en) 2021-05-20
JP7395607B2 (ja) 2023-12-11
JP2024026205A (ja) 2024-02-28
WO2021095092A1 (ja) 2021-05-20
AU2020384456A1 (en) 2022-06-09
JP7676510B2 (ja) 2025-05-14
EP4059502A1 (en) 2022-09-21
JP2025118718A (ja) 2025-08-13
US20220387423A1 (en) 2022-12-08
JPWO2021095779A1 (https=) 2021-05-20

Similar Documents

Publication Publication Date Title
TWI634908B (zh) 包含有７－［４－（４－苯并［ｂ］噻吩－４－基－哌－１－基）丁氧基］－１Ｈ－喹啉－２－酮或其鹽之錠劑
JP5352474B2 (ja) 口腔内崩壊錠およびその製造方法
EP2832350B1 (en) Method for producing disintegrating particulate composition comprising acid-type carboxymethylcellulose, disintegrating particulate composition comprising acid-type carboxymethylcellulose, and orally disintegrating tablet including disintegrating particulate composition comprising acid-type carboxymethylcellulose
US20100285164A1 (en) Orally Disintegrating Excipient
CN104159583B (zh) 含有1‑(3‑(2‑(1‑苯并噻吩‑5‑基)乙氧基)丙基)氮杂环丁烷‑3‑醇或其盐的固体药物组合物
JP2025118718A (ja) 口腔内崩壊錠
EP3501506B1 (en) Pharmaceutical tablet composition comprising brexpiprazole
JP5342028B2 (ja) 口腔内崩壊錠
JP2019112424A (ja) トホグリフロジンを含有する固形製剤及びその製造方法
JP4759102B2 (ja) 経口投与用医薬組成物
CN101405004A (zh) 新型薄膜衣片剂
JP7486258B2 (ja) 口腔内崩壊錠用顆粒、その製造方法および口腔内崩壊錠
HK40071352A (en) Orally disintegrating tablet
EP1862184A1 (en) Pharmaceutical composition
HK40066890A (zh) 口腔崩解片剂
EA051121B1 (ru) Перорально распадающаяся таблетка
EP4157262A1 (en) Pharmaceutical formulations of pilocarpine r-(+)-lipoate
TW202108130A (zh) 含維格列汀乾式造粒粉、含維格列汀錠劑及其製造方法
CN106913535A (zh) 一种ddp-4抑制剂药物口崩片及其制备方法
JP7680822B2 (ja) 糖尿病治療剤
JP2018048136A (ja) 錠剤およびその製造方法
JP6668666B2 (ja) イルベサルタンを含有する医薬組成物及びその製造方法
JP2003095946A (ja) ファモチジン錠剤
TW201422224A (zh) 含有達泊西汀游離鹼的口腔用組成物
HK1111619A (en) Pharmaceutical composition